Science Advisory Committee 

William Foulkes (Chair)

McGill Centre for Translational Research in Cancer, Canda

Rachel Butler 

North Bristol NHS Trust
Majorlijn Ligtenberg

Radboud University Medical Center, Netherlands
Mary Porteous

University of Edinburgh

Our Science Advisory Committee consists of four independent members drawn from leading scientists broadly representing the programme diversity.

The committee meet annually, along with CRUK and PPI representation, to monitor progress and provide scientific evaluation of the CGCV program of research to the programme and work-package leads. The feedback received from the SAC is used to direct future research and program strategy.

Patient Reference Panel

Lesley Turner (Chair)

Independent Cancer Patient Voices

Helen White

Pete Wheatstone 

Carolyn Dale

Rochelle Gold 

The Patient Reference Panel (PRP) will be made up of 'research partners': patients, carers and members of the public who are affected by cancer and have an interest in genetics. 

The PRP has been set up to for our research partners, working together with our research team, to look at how the CanGene-CanVar programme is set up and running, to make sure it is in the best interests of those who may be considering genetic testing, as well as making sure of good research outcomes. 

CanVIG Steering and Advisory Committee (CStAG)

Alison Calloway (Co-Chair)

Salisbury NHS Foundation Trust

Miranda Durkie (Co-Chair)

Sheffield University Hospitals NHS Foundation Trust

Rachel Robinson

Leeds Teaching Hospitals NHS Trust
George Burghel

Manchester University NHS Foundation Trust
James Drummond

Cambridge University Hospitals NHS Trust
Ian Berry

Leeds Teaching Hospitals NHS Trust 
Andrew Wallace

Manchester University NHS Foundation Trust

CStAG is formed of NHS Clinical Laboratory Scientist representatives from across the UK. 

The committee has been established from members of CanVIG, a group formed to improve the consistency of cancer genetic variant interpretation in the UK. The members are focussing the working priorities of CanVIG-UK and are an expert group of advisors supporting work-package 2

Primary Care Panel

Imran Rafi

Senior Lecturer St George's University of London
RCGP Joint Clinical Champion Genomics
GP Surrey Downs

Judith Hayward 

GPwSI in Genetics, Yorkshire and Humber Genomics Medicine Centre; Primary Care Adviser to Health Education England Genomics Education Programme; RCGP Joint Clinical Champion in Genomics Medicine; GP, Shipley Medical Practice, Affinity Care

As RCGP Joint Clinical Champions in Genomics facilitating the adoption and diffusion of new knowledge within primary care, our panel leads have a wealth of expertise to contribute across the CGCV programme.

The wider panel membership remains flexible to suit the needs of programme, with Imran and Judith acting as a point of liaison between CGCV researchers and the primary care community. In particular, the panel are involved with external review of clinical guidelines developed in work-package 3. 

Oncology Panel

Ellen Copson (Chair)

University Hospital Southampton Foundation NHS Trust; Associate Professor in Medical Oncology, University of Southampton

Dr Copson is a practising medical oncologist interested in precision medicine and germline cancer susceptibility, as well as national lead for the oncogenetics training working party.


The oncology panel membership will be flexible to suit the different needs across the CGCV programme. In particular, our clinical education work-package (5) investigators will be collaborating with the oncogenetics training working party and oncologists will also be involved in external review of clinical guidelines developed in work-package 3.

Clinical Guideline Group

Anjana Kulkani (Chair)

Guy's and St Thomas' NHS Foundation Trust

Julian Adlard 

Yorkshire and North East

Kei-Ren Ong 

Wessex and West Midlands

Muna Ahmed

London North

Carole Brewer

South West

Alex Murray, Tabib Dahir

Devolved Nations

Other regions are represented by our work package investigators

The Clinical Guideline Group supports work package 3 and is formed of Clinical Genetics specialists representing all regions of the UK. 

The group is involved at every stage of guideline development, as they review the evidence collated by work-package staff and establish consensus recommendations (clinical guidelines) for genetic testing and management of patients at elevated genetic risk of cancer. 


The work of the group is also sent for external review by gene-specific experts, our primary care and oncology panels, work-package 4 genetic counsellor, and patient representatives.